Figure 5.

FTVII-Treated regulatory T cells traffic preferentially to bone marrow. (A) Depicts the schematic for model of xenogeneic graft vs host disease, noting the simultaneous use of PBMCs for disease initiation and initiation of nvTreg expansion cultures. (B) The ability of FTVII treatment to affect tissue migration was tested by co-injecting (i.v.) expanded nvTregs that were buffer or FTVII- treated, and differentially labeled with CFSE or SNARF, into NSG mice 14 days after the injection of 10⁷ PBMCs. After 24 hours, the frequency of Tregs in the bone marrow, lung, spleen, and liver was determined by FACS as compared to the number of human cells in each tissue as determined by staining for human CD45. Data are shown as mean ± SEM. Significance was determined by Student’s t test (*P < 0.05).